The high percentage of ephrin-A3-positive T cells of patients with RR-MS was mainly due to the significantly high percentage of ephrin-A3-positive CD4+ T cells (5.2 ± 1.2%), CD8+ T cells (9.1 ± 1.5%) and Tregs (7.0 ± 1.8%) of patients with RR-MS compared to HC (1.4 ± 0.4%, p = 0.003; 3.8 ± 1.0%, p = 0.005 and 2.8 ± 0.6%, p = 0.031, respectively, Figure 2C). This evidence concerns the gene CD8A and myeloid sarcoma.